The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo.

OBJECTIVE Pioglitazone is a member of the thiazolidinediones (TZDs), insulin-sensitizing agents used to treat type 2 diabetes. The aim of this study was to define the effect of pioglitazone on the expression of genes related to carbohydrate and lipid metabolism in subcutaneous fat obtained from type 2 diabetic patients. RESEARCH DESIGN AND METHODS Forty-eight volunteers with type 2 diabetes were divided into two groups treated for 12 weeks with placebo or pioglitazone (30 mg/day). The expression of several genes was quantified by real-time RT-PCR. RESULTS Pioglitazone treatment increased the expression of genes involved in glycerol-3-phosphate synthesis. The mRNA expression of PEPCK-C and glycerol-3-phosphate dehydrogenase (GPDH) increased (P < 0.01) in patients treated with pioglitazone. There was no difference in glycerol kinase (GyK) mRNA levels. The expression of genes that regulate fatty acid availability in adipocytes, including lipoprotein lipase (LPL) and acetyl-CoA synthetase (ACS), was higher (P < 0.01) in pioglitazone-treated patients. Pioglitazone stimulated (P < 0.0001) expression of c-Cbl-associated protein (CAP), whereas tumor necrosis factor-alpha, leptin, resistin, angiopoietin like-4, and 11-beta-hydroxysteroid dehydrogenase type 1 (11beta HSD 1) were not affected by pioglitazone. The baseline peroxisome proliferator-activated receptor (PPAR)-gamma1 mRNA was significantly correlated with mRNA for LPL, CAP, ACS, 11beta HSD 1, GyK, fatty acid synthase, leptin, and GPDH, whereas PPAR-gamma2 mRNA was correlated with CAP, PEPCK-C, leptin, and GPDH. CONCLUSIONS Treatment with pioglitazone increased body weight, and this is associated with upregulation of some, but not all, genes previously demonstrated as "TZD responsive" in subcutaneous fat. The results suggest that TZDs might increase body weight through the upregulation of genes facilitating adipocyte lipid storage in vivo.

[1]  M. Hellerstein,et al.  Adipose tissue triglyceride turnover, de novo lipogenesis, and cell proliferation in humans measured with 2H2O. , 2004, American journal of physiology. Endocrinology and metabolism.

[2]  J. Stephens,et al.  Agouti expression in human adipose tissue: functional consequences and increased expression in type 2 diabetes. , 2003, Diabetes.

[3]  S. Tilghman,et al.  Glyceroneogenesis and the Triglyceride/Fatty Acid Cycle* , 2003, Journal of Biological Chemistry.

[4]  F. Karpe,et al.  A “futile cycle” induced by thiazolidinediones in human adipose tissue? , 2003, Nature Medicine.

[5]  L. J. Hardies,et al.  Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. , 2003, Diabetes.

[6]  S. Shioda,et al.  Lipoprotein lipase mRNA in white adipose tissue but not in skeletal muscle is increased by pioglitazone through PPAR-gamma. , 2003, Biochemical and biophysical research communications.

[7]  J. Tordjman,et al.  Thiazolidinediones Block Fatty Acid Release by Inducing Glyceroneogenesis in Fat Cells* , 2003, Journal of Biological Chemistry.

[8]  Khan Ah,et al.  Insulin regulation of glucose uptake: a complex interplay of intracellular signalling pathways. , 2002 .

[9]  R. Hammer,et al.  Glyceroneogenesis comes of age , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  M. Lazar,et al.  A futile metabolic cycle activated in adipocytes by antidiabetic agents , 2002, Nature Medicine.

[11]  H. Hauner.  The mode of action of thiazolidinediones , 2002, Diabetes/metabolism research and reviews.

[12]  T. Saruta,et al.  Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. , 2002, Metabolism: clinical and experimental.

[13]  Vincent Lebon,et al.  The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. , 2002, Diabetes.

[14]  M. Lazar,et al.  Resistin and obesity-associated insulin resistance , 2002, Trends in Endocrinology & Metabolism.

[15]  A. Garg,et al.  A Novel Heterozygous Mutation in Peroxisome Proliferator-Activated Receptor-γ Gene in a Patient with Familial Partial Lipodystrophy , 2002 .

[16]  J. Pessin,et al.  Insulin regulation of glucose uptake: a complex interplay of intracellular signalling pathways , 2002, Diabetologia.

[17]  R. Plodkowski,et al.  Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects. , 2002, Diabetes.

[18]  M. Matsuda,et al.  Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients , 2001, Diabetologia.

[19]  B. Spiegelman,et al.  PPARγ: a Nuclear Regulator of Metabolism, Differentiation, and Cell Growth* , 2001, The Journal of Biological Chemistry.

[20]  D. Scott,et al.  A single element in the phosphoenolpyruvate carboxykinase gene mediates thiazolidinedione action specifically in adipocytes. , 2001, Biochimie.

[21]  Wei Chen,et al.  Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. , 2001, Diabetes.

[22]  R. Thieringer,et al.  Peroxisome Proliferator-activated Receptor-γ Ligands Inhibit Adipocyte 11β-Hydroxysteroid Dehydrogenase Type 1 Expression and Activity* , 2001, The Journal of Biological Chemistry.

[23]  S. Kalhan,et al.  Glyceroneogenesis and the Source of Glycerol for Hepatic Triacylglycerol Synthesis in Humans* , 2001, The Journal of Biological Chemistry.

[24]  J. Auwerx,et al.  The expression of the p85α subunit of phosphatidylinositol 3-Kinase is induced by activation of the peroxisome proliferator-activated receptor γ in human adipocytes , 2001, Diabetologia.

[25]  T. Willson,et al.  Comprehensive Messenger Ribonucleic Acid Profiling Reveals That Peroxisome Proliferator-Activated Receptor γ Activation Has Coordinate Effects on Gene Expression in Multiple Insulin-Sensitive Tissues. , 2001, Endocrinology.

[26]  B. Spiegelman,et al.  Peroxisome Proliferator-Activated Receptor γ Target Gene Encoding a Novel Angiopoietin-Related Protein Associated with Adipose Differentiation , 2000, Molecular and Cellular Biology.

[27]  A. Saltiel,et al.  Cloning and Characterization of a Functional Peroxisome Proliferator Activator Receptor-γ-responsive Element in the Promoter of the CAP Gene* , 2000, The Journal of Biological Chemistry.

[28]  S. O’Rahilly,et al.  Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension , 1999, Nature.

[29]  M. Lean,et al.  Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. , 1999, Diabetes care.

[30]  J. H. Johnson,et al.  Thiazolidinediones and insulin resistance: peroxisome proliferatoractivated receptor gamma activation stimulates expression of the CAP gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[31]  S. Mudaliar,et al.  Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve up-regulation of peroxisome proliferator-activated receptor-gamma. , 1998, The Journal of clinical endocrinology and metabolism.

[32]  J. Auwerx,et al.  PPARgamma activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. , 1998, Atherosclerosis.

[33]  B. Spiegelman.  PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. , 1998, Diabetes.

[34]  N. Hoffman,et al.  A Novel, Multifunctional c-Cbl Binding Protein in Insulin Receptor Signaling in 3T3-L1 Adipocytes , 1998, Molecular and Cellular Biology.

[35]  S. O’Rahilly,et al.  Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. , 1997, The Journal of clinical investigation.

[36]  J. Auwerx,et al.  4.P.263 Coordinate regulation of the expression of the fatty acid transporter protein (FATP) and acyl CoA synthetase (ACS) genes by PPARα and PPARγ activators , 1997 .

[37]  J. Auwerx,et al.  Pioglitazone Induces In Vivo Adipocyte Differentiation in the Obese Zucker fa/fa Rat , 1997, Diabetes.

[38]  J. Auwerx,et al.  The Organization, Promoter Analysis, and Expression of the Human PPARγ Gene* , 1997, The Journal of Biological Chemistry.

[39]  M. Jimenez-Linan,et al.  Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. , 1997, The Journal of clinical investigation.

[40]  J Auwerx,et al.  PPARalpha and PPARgamma activators direct a distinct tissue‐specific transcriptional response via a PPRE in the lipoprotein lipase gene. , 1996, The EMBO journal.

[41]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.